Cover Image
市場調查報告書

Hutchison MediPharma Limited:產品平台分析

Hutchison MediPharma Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 255990
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
Hutchison MediPharma Limited:產品平台分析 Hutchison MediPharma Limited - Product Pipeline Review - 2015
出版日期: 2015年08月26日 內容資訊: 英文 49 Pages
簡介

Hutchison MediPharma Limited是Hutchison China MediTech Limited的子公司,是總公司設置於中國的製藥企業。正在從事腫瘤及自體免疫疾病治療藥之藥物研發、開發、商品化。藥物研發利用分子生物學,細胞生物學,高通量篩檢,基因工程學,資訊學等技術。

本報告提供Hutchison MediPharma Limited的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Hutchison MediPharma Limited 基本資料

  • Hutchison MediPharma Limited 概要
  • 主要資訊
  • 企業資料

Hutchison MediPharma Limited :R&D概要

  • 主要的治療範圍

Hutchison MediPharma Limited :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Hutchison MediPharma Limited :開發中產品概況

  • 後期階段產品開發中產品
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • IND/CTA登記前的產品/聯合治療模式
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Hutchison MediPharma Limited :藥物簡介

  • HMPL-013
  • HMPL-504
  • HMPL-012
  • HMPL-309
  • HMPL-523
  • HMPL-813
  • HM-029
  • HM-032
  • HM-5016699
  • HMPL-453
  • HMPL-507
  • HMPL-689
  • HMPL-518

Hutchison MediPharma Limited :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Hutchison MediPharma Limited:最近的開發平台形勢

Hutchison MediPharma Limited:開發暫停中的計劃

Hutchison MediPharma Limited:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07425CDB

Summary

Global Markets Direct's, 'Hutchison MediPharma Limited - Product Pipeline Review - 2015', provides an overview of the Hutchison MediPharma Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Hutchison MediPharma Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Hutchison MediPharma Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Hutchison MediPharma Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Hutchison MediPharma Limited's pipeline products

Reasons to buy

  • Evaluate Hutchison MediPharma Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Hutchison MediPharma Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Hutchison MediPharma Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Hutchison MediPharma Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hutchison MediPharma Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Hutchison MediPharma Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Hutchison MediPharma Limited Snapshot
    • Hutchison MediPharma Limited Overview
    • Key Information
    • Key Facts
  • Hutchison MediPharma Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Hutchison MediPharma Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Hutchison MediPharma Limited - Pipeline Products Glance
    • Hutchison MediPharma Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Hutchison MediPharma Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Hutchison MediPharma Limited - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Hutchison MediPharma Limited - Drug Profiles
    • HMPL-013
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-504
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-012
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-309
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-523
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-813
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HM-029
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HM-032
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HM-5016699
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-453
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-507
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-689
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-518
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hutchison MediPharma Limited - Pipeline Analysis
    • Hutchison MediPharma Limited - Pipeline Products by Target
    • Hutchison MediPharma Limited - Pipeline Products by Route of Administration
    • Hutchison MediPharma Limited - Pipeline Products by Molecule Type
    • Hutchison MediPharma Limited - Pipeline Products by Mechanism of Action
  • Hutchison MediPharma Limited - Recent Pipeline Updates
  • Hutchison MediPharma Limited - Dormant Projects
  • Hutchison MediPharma Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Hutchison MediPharma Limited, Key Information
  • Hutchison MediPharma Limited, Key Facts
  • Hutchison MediPharma Limited - Pipeline by Indication, 2015
  • Hutchison MediPharma Limited - Pipeline by Stage of Development, 2015
  • Hutchison MediPharma Limited - Monotherapy Products in Pipeline, 2015
  • Hutchison MediPharma Limited - Phase III, 2015
  • Hutchison MediPharma Limited - Phase II, 2015
  • Hutchison MediPharma Limited - Phase I, 2015
  • Hutchison MediPharma Limited - IND/CTA Filed, 2015
  • Hutchison MediPharma Limited - Preclinical, 2015
  • Hutchison MediPharma Limited - Discovery, 2015
  • Hutchison MediPharma Limited - Pipeline by Target, 2015
  • Hutchison MediPharma Limited - Pipeline by Route of Administration, 2015
  • Hutchison MediPharma Limited - Pipeline by Molecule Type, 2015
  • Hutchison MediPharma Limited - Pipeline Products by Mechanism of Action, 2015
  • Hutchison MediPharma Limited - Recent Pipeline Updates, 2015
  • Hutchison MediPharma Limited - Dormant Developmental Projects,2015
  • Hutchison MediPharma Limited, Other Locations

List of Figures

  • Hutchison MediPharma Limited - Pipeline by Top 10 Indication, 2015
  • Hutchison MediPharma Limited - Pipeline by Stage of Development, 2015
  • Hutchison MediPharma Limited - Monotherapy Products in Pipeline, 2015
  • Hutchison MediPharma Limited - Pipeline by Top 10 Target, 2015
  • Hutchison MediPharma Limited - Pipeline by Top 10 Route of Administration, 2015
  • Hutchison MediPharma Limited - Pipeline by Top 10 Molecule Type, 2015
  • Hutchison MediPharma Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top